Shots:

• The 2 P-III ILLUMINATE SWITCH A & B trials evaluate doravirine/islatravir (100/0.75mg- qd- PO) in a ratio (1:1) in 672 & 641 patients with HIV-1 who are virologically suppressed on different ART regimens or BIC/FTC/TAF
• Both the trials met its primary efficacy EPs i.e.- the proportion of patients with HIV-1 RNA levels ≥50 copies/mL demonstrated an antiviral efficacy b/w DOR/ISL & ART (ILLUMINATE SWITCH A) and DOR/ISL & BIC/FTC/TAF (ILLUMINATE SWITCH B) @ 48wks.- safety & tolerability are consistent with the previously reported P-II studies
• Doravirine is approved for HIV-1 in combination with other antiretrovirals as monothx. Pifeltro & Delstrigo. Islatravir is Merck’s NRTTIs inhibitor

 ­ Ref: Merck | Image: Merck